Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750—an antisense oligonucleotide against eIF4E—in combination with irinotecan in solid tumors and irinotecan-refractory colorectal cancer

International Journal of Cancer

Volumn 139, Issue 7, 2016, Pages 1648-1657

  Duffy, A G ^a   Makarova Rusher, O V ^a   Ulahannan, S V ^a   Rahma, O E ^a   Fioravanti, S ^a   Walker, M ^a   Abdullah, S ^a   Raffeld, M ^a   Anderson, V ^a   Abi Jaoudeh, N ^a   Levy, E ^a   Wood, B J ^a   Lee, S ^a   Tomita, Y ^a   Trepel, J B ^a   Steinberg, S M ^a   Revenko, A S ^b   MacLeod, A R ^b   Peer, C J ^a   Figg, W D ^a   Greten, T F ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b ISIS PHARMACEUTICALS   (United States)

Author keywords

antisense; colorectal cancer; eIF4E

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTISENSE OLIGODEOXYNUCLEOTIDE; INITIATION FACTOR 4E; IRINOTECAN; ISIS 183750; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ANTISENSE THERAPY; AREA UNDER THE CURVE; ARTICLE; CANCER CONTROL; CANCER SURVIVAL; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL ARTICLE; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG SAFETY; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG TRANSPORT; FATIGUE; FEMALE; HCT116 CELL LINE; HUMAN; HUMAN TISSUE; HYPOALBUMINEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; IMMUNOHISTOCHEMISTRY; LYMPHOCYTOPENIA; MALE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SOLID TUMOR; THROMBOCYTOPENIA; VOMITING;

EID: 84978280537     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30199     Document Type: Article

References (24)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277–300.
2. Grothey A, Sargent D, Goldberg RM, et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004;22:1209–14.
3. Grothey A, Sugrue MM, Purdie DM, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008;26:5326–34.
4. Grothey E, Chu E. The clinical efficacy of FOLFIRI and bevacizumab in combination as first-line therapy of metastatic colorectal cancer. Clin Colorectal Cancer 2007;6:621–4.
5. Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 2014;15:1065–75.
6. Borden KL. Targeting the oncogene eIF4E in cancer: from the bench to clinical trials. Clin Invest Med 2011;34:E315.
7. De Benedetti A, Graff JR. eIF-4E expression and its role in malignancies and metastases. Oncogene 2004;23:3189–99.
8. Chen X, Peer CJ, Alfaro R, et al. Quantification of irinotecan, SN38, and SN38G in human and porcine plasma by ultra high-performance liquid chromatography-tandem mass spectrometry and its application to hepatic chemoembolization. J Pharm Biomed Anal 2012;62:140–8.
9. Kordasiewicz HB, Stanek LM, Wancewicz EV, Mazur C, McAlonis MM, Pytel KA, Artates JW, Weiss A, Cheng SH, Shihabuddin LS, Hung G, Bennett CF, Cleveland DW. Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron. 2012 Jun 21;74(6):1031–1044.
10. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1–10.
11. Younis IR, Malone S, Friedman HS, et al. Enterohepatic recirculation model of irinotecan (CPT-11) and metabolite pharmacokinetics in patients with glioma. Cancer Chemother Pharmacol 2009;63:517–24.
12. Canal P, Gay C, Dezeuze A, et al. Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 1996;14:2688–95.
13. Graff JR, Zimmer SG. Translational control and metastatic progression: enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs. Clin Exp Metastasis 2003;20:265–73.
14. Berkel HJ, Turbat-Herrera EA, Shi R, et al. Expression of the translation initiation factor eIF4E in the polyp-cancer sequence in the colon. Cancer Epidemiol Biomarkers Prev 2001;10:663–6.
15. Rosenwald IB, Chen JJ, Wang S, et al. Upregulation of protein synthesis initiation factor eIF-4E is an early event during colon carcinogenesis. Oncogene 1999;18:2507–17.
16. Provenzani A, Fronza R, Loreni F, et al. Global alterations in mRNA polysomal recruitment in a cell model of colorectal cancer progression to metastasis. Carcinogenesis 2006;27:1323–33.
17. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337–45.
18. Stephenson ML, Zamecnik PC. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc Natl Acad Sci USA 1978;75:285–8.
19. Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA 1978;75:280–4.
20. Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 2010;50:259–93.
21. Yanagiya A, Suyama E, Adachi H, et al. Translational homeostasis via the mRNA cap-binding protein, eIF4E. Mol Cell 2012;46:847–58.
22. Chi KN, Eisenhauer E, Fazli L, et al. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 2005;97:1287–96.
23. Seth PP, Siwkowski A, Allerson CR, et al. Short antisense oligonucleotides with novel 2'-4' conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals. J Med Chem 2009;52:10–13.
24. Hong D, Kim Y, Younes A, et al. Abstract LB-227: preclinical pharmacology and clinical efficacy of AZD9150 (ISIS-STAT3Rx), a potent next-generation antisense oligonucleotide inhibitor of STAT3. Cancer Res 2014;74:LB-227.